full data top-line ahead
ep came ahead expect due non-oper incom
lower tax rate ep guidanc due lower tax rate
howev stock still somewhat weak given lower qualiti natur
beat rapid eros see sale zepati zostavax
sale believ caution ahead monday earn key
competitor continu see valu expect see
upsid see full data well top-line data
two less appreci trial non-smal cell lung cancer keynote-
keytruda monotherapi patient level posit
keytruda abraxan squamou lung cancer base
follow convers compani remain confid
present mid-april see
top-line data come month
notabl model updat increas global sale estim
keytruda/i-o franchis cs estim
hand acceler eros zepati
zostavax new competitor aggress take market share
expens assum oper expens increas due
increas spend lower tax rate line
guidanc follow modest adjust model
expect ep
target price slip blue sky
valuat grey sky valuat reiter
outperform rate ahead import upcom catalyst primari
risk view poor execut commerci opportun
keytruda and/or disappoint clinic data pleas let us know
would like updat compani model
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
follow-up manag
opportun speak member team follow
confer call gain addit clariti dynam around certain product
well bake expect around fy
summar compani answer question
tax mean
last data point would indefinit shore cash
cash would spent sinc
balanc last balanc sheet rang
off-shore
tax base off-shore held earn
also depend cash cash
disclos exact level cash brought back look
follow
focus oncolog vaccin anim health
earli discoveri hub build
cyber attack last quarter impact residu issu
small continu impact fulli consid guidanc
guidanc base restat number restat
offici come
includ consid guidanc sinc base restat number
sure exactli
clear answer use doubt use new number
lynparza keytruda combo upcom readout
combo studi get start data come soon
lynparza monotherapi next year
combo data longer term
ovarian upcom
alway consid combo upsid potenti
dont provid other
major patient keytruda
see increas group
start see progress group take time
awar issu combat
keytruda data
clearli next
tnb toward end year
zostavax declin entir quarter inflect point
data expect overal trend continu
expect newli launch product
expect whole diabet franchis stabl
build year steglatro
convers payer on-going
cycl approv impact abil gain traction
approv novemb patient stem cell transplant
data patient solid organ transplant still pend bigger
fda action date come octob
much contribut
want build combo time frame
part full portfolio excit
major shift statu variou pipelin drug
keytruda lung readout discuss
potenti japan approv breast
ovarian trial
selumetinib point year
phase start sometim year
expect
see data hard comment
data would strong either direct read-through
target data take time
convers dont know yet
ex-u quarter saw uptak pressur grow
time pressur vari market
decreas volum similar us
declin across mani major market
expect pressur continu beyond
month stay earli
dont think year
clinic
els clinic
recent disclosur show slide
talk intern provid info investor
us million unless otherwis state
us million unless otherwis state
us million unless otherwis state
us million unless otherwis state
us million unless otherwis state
merck co inc global health care compani deliv health
solut prescript medicin market
joint ventur oper segment
anim health consum allianc
price feb rate outperform target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
blue sky valuat base greater sale
keytruda januvia gardasil compar current base case
assumpt also model higher gross margin oper
margin base case assumpt blue sky valuat
base dcf driven wacc termin valu
grey sky valuat base lower sale
keytruda januvia gardasil compar current base case
assumpt also model lower gross margin oper
margin base assumpt grey sky valuat base
dcf driven wacc termin valu
compani mention price
